Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: erickerickson who wrote (46208)	5/23/2018 12:06:06 PM
From: EagleRare	2 Recommendations Recommended By ladyPI moverman Read Replies (1) \| Respond to of 63276

The business plan can not be underestimated. IMMU is trying to build itself up as a standalone biopharmaceutical company. If you see how the management is executing (i.e. focus on IMMU-132 for AA, establishment of manufacturing, initiating the Phase III, hiring the extensive sales staff, submitting the BLA, securing ample financing through the royalty agreement, hiring effective and accomplished management), then you understand the room for growth in ones investment is great.

To: erickerickson who wrote (46208)	5/23/2018 2:04:10 PM
From: Fitzhughlaw	8 Recommendations Recommended By erickerickson Just Paul ladyPI mrc758 Oiji and 3 more members Read Replies (1) \| Respond to of 63276

They must respect and not taunt the power of the gris gris, and thus thou shalt not mention or even advert to the PPS during a trading session. At the risk of being serious, we all have computers and stock tickers, and most here can read at or above a 4th grade level, so posts such as "$xx.xx print" at 4:01 pm and jibber jabber about the PPS at a given point during a trading session are not necessary or welcomed (unless there are three integers to the left of the decimal point - in that case, we will consider something less than the death penalty).